Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
FOLDAmicus Therapeutics(FOLD) Zacks Investment Research·2024-05-10 11:30

For the quarter ended March 2024, Amicus Therapeutics (FOLD) reported revenue of 110.4million,up28110.4 million, up 28% over the same period last year. EPS came in at -0.02, compared to -0.18intheyear−agoquarter.ThereportedrevenuecomparestotheZacksConsensusEstimateof0.18 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of 111.62 million, representing a surprise of -1.09%. The company delivered an EPS surprise of +66.67%, with the consensus EPS estimate being -$0.06. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings ...